TWD 24.5
(1.24%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 318.12 Million TWD | 4.07% |
2022 | 305.21 Million TWD | 27.71% |
2021 | 238.98 Million TWD | 13.11% |
2020 | 211.28 Million TWD | -9.31% |
2019 | 232.96 Million TWD | 4.99% |
2018 | 226.13 Million TWD | -6.34% |
2017 | 250.94 Million TWD | -8.94% |
2016 | 272.53 Million TWD | -21.31% |
2015 | 330.65 Million TWD | -9.26% |
2014 | 364.4 Million TWD | 17.13% |
2013 | 311.45 Million TWD | -5.47% |
2012 | 319.74 Million TWD | 5.01% |
2011 | 285.84 Million TWD | 14.71% |
2010 | 240.84 Million TWD | -15.48% |
2009 | 309.26 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 78.39 Million TWD | 17.37% |
2024 Q2 | 52.64 Million TWD | -26.39% |
2023 Q3 | 64.69 Million TWD | -36.15% |
2023 Q4 | 61.43 Million TWD | -5.04% |
2023 FY | - TWD | 4.07% |
2023 Q1 | 90.18 Million TWD | 99.47% |
2023 Q2 | 101.32 Million TWD | 12.35% |
2022 Q2 | 93.63 Million TWD | 41.32% |
2022 Q4 | 45.21 Million TWD | -54.84% |
2022 FY | - TWD | 27.71% |
2022 Q3 | 100.1 Million TWD | 6.91% |
2022 Q1 | 66.25 Million TWD | 88.68% |
2021 Q3 | 72.53 Million TWD | 11.25% |
2021 Q4 | 35.11 Million TWD | -51.58% |
2021 Q1 | 66.13 Million TWD | 78.89% |
2021 Q2 | 65.19 Million TWD | -1.41% |
2021 FY | - TWD | 13.11% |
2020 Q2 | 82.77 Million TWD | 132.19% |
2020 Q1 | 35.65 Million TWD | -39.08% |
2020 FY | - TWD | -9.31% |
2020 Q4 | 36.96 Million TWD | -33.85% |
2020 Q3 | 55.88 Million TWD | -32.49% |
2019 Q3 | 48.1 Million TWD | -9.48% |
2019 FY | - TWD | 4.99% |
2019 Q1 | 71.81 Million TWD | 8.98% |
2019 Q2 | 53.13 Million TWD | -26.01% |
2019 Q4 | 58.52 Million TWD | 21.67% |
2018 Q1 | 49.98 Million TWD | 62.38% |
2018 FY | - TWD | -6.34% |
2018 Q4 | 65.89 Million TWD | 25.75% |
2018 Q3 | 52.4 Million TWD | -2.26% |
2018 Q2 | 53.61 Million TWD | 7.28% |
2017 Q4 | 30.78 Million TWD | -50.58% |
2017 Q1 | 59.55 Million TWD | 33.38% |
2017 Q3 | 62.27 Million TWD | -26.14% |
2017 Q2 | 84.31 Million TWD | 41.57% |
2017 FY | - TWD | -8.94% |
2016 FY | - TWD | -21.31% |
2016 Q1 | 85.82 Million TWD | 2.32% |
2016 Q2 | 77.81 Million TWD | -9.33% |
2016 Q3 | 51.89 Million TWD | -33.31% |
2016 Q4 | 44.65 Million TWD | -13.95% |
2015 Q4 | 83.88 Million TWD | 97.86% |
2015 Q3 | 42.39 Million TWD | -59.37% |
2015 Q2 | 104.34 Million TWD | 4.32% |
2015 Q1 | 100.02 Million TWD | 95.0% |
2015 FY | - TWD | -9.26% |
2014 Q4 | 51.29 Million TWD | -46.71% |
2014 Q3 | 96.25 Million TWD | -17.5% |
2014 Q1 | 100.18 Million TWD | 21.94% |
2014 FY | - TWD | 17.13% |
2014 Q2 | 116.67 Million TWD | 16.46% |
2013 Q4 | 82.15 Million TWD | 54.73% |
2013 FY | - TWD | -5.47% |
2013 Q3 | 53.09 Million TWD | -43.21% |
2013 Q2 | 93.49 Million TWD | 13.51% |
2013 Q1 | 82.36 Million TWD | 0.75% |
2012 Q1 | 81.14 Million TWD | 9.35% |
2012 FY | - TWD | 5.01% |
2012 Q3 | 64.51 Million TWD | -30.21% |
2012 Q2 | 92.44 Million TWD | 13.93% |
2012 Q4 | 81.74 Million TWD | 26.71% |
2011 Q1 | 100.94 Million TWD | 222.08% |
2011 FY | - TWD | 14.71% |
2011 Q2 | 65.36 Million TWD | -35.25% |
2011 Q3 | 72.87 Million TWD | 11.49% |
2011 Q4 | 74.2 Million TWD | 1.83% |
2010 Q3 | 74.71 Million TWD | -18.09% |
2010 FY | - TWD | -15.48% |
2010 Q4 | 31.34 Million TWD | -58.05% |
2010 Q1 | 75.94 Million TWD | 0.0% |
2010 Q2 | 91.21 Million TWD | 20.1% |
2009 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Excelsior Medical Co., Ltd. | 968.55 Million TWD | 67.155% |
OK Biotech Co., Ltd. | 87.24 Million TWD | -264.636% |
Applied BioCode Corporation | -98.59 Million TWD | 422.669% |